Understanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practices
Open Access
- 1 March 2011
- journal article
- research article
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. 5, 173-180
Abstract
Background: All established disease-modifying drugs for multiple sclerosis require parenteral administration, which can cause difficulties for some patients, sometimes leading to suboptimal adherence. A new electronic autoinjection device has been designed to address these issues. Methods: Patients with relapsing multiple sclerosis currently receiving subcutaneous or intramuscular interferon beta-1a, interferon beta-1b, or glatiramer acetate completed an online questionnaire (July 4–25, 2008) that surveyed current injection practices, experiences with current injection methods, and impressions and appeal of the new device. Results: In total, 422 patients completed the survey, of whom 44% used autoinjectors, 43% prefilled syringes, and 13% syringes and vials; overall, 66% currently self-injected. Physical and psychological barriers to self-injection included difficulty with injections, needle phobia, and concerns over correct injection technique. Only 40% of respondents were “very satisfied” with their current injection method. The new electronic autoinjector was rated as “very appealing” by 65% of patients. The benefits of the new device included the ability to customize injection settings and to review dosing history. Conclusion: New technologies may help patients overcome physical and psychological barriers to self-injection. The combination of a reliable and flexible autoinjection device with dose-monitoring technology may improve communication between health care professionals and patients, and improve treatment adherence.Keywords
This publication has 11 references indexed in Scilit:
- The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosisEuropean Journal of Neurology, 2010
- Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb studyBMC Neurology, 2010
- Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?Expert Opinion on Drug Delivery, 2009
- Factors that influence adherence with disease-modifying therapy in MSJournal of Neurology, 2009
- Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term.2008
- Safety and Tolerability in Relapsing-Remitting Multiple Sclerosis Patients Treated With High-Dose Subcutaneous Interferon-Beta by Rebiject Autoinjection Over a 1-Year PeriodClinical Neuropharmacology, 2008
- Réduction des réactions cutanées aux points d’injection avec deux auto-injecteurs chez des patients ayant une sclérose en plaques rémittente débutant un traitement par interféron bêta-1b: étude randomisée en cross-overRevue Neurologique, 2006
- Multiple Sclerosis: New Insights and Trends2006
- Incidence and Prevalence of Multiple Sclerosis in Newfoundland and LabradorCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2005
- A prospective study of the incidence, prevalence and mortality of multiple sclerosis in LeedsJournal of Neurology, 2000